Re-purposing cancer therapeutics for breast cancer immunotherapy

Leisha A. Emens

Research output: Contribution to journalArticle

Abstract

After decades of work to develop immunebased therapies for cancer, the Wrst drugs designed speciWcally to engage the host anti-Tumor immune response for therapeutic beneWt were recently approved for clinical use. Sipuleucel-T, a vaccine for advanced prostate cancer, and ipilimumab, a monoclonal antibody that mitigates the negative impact of cytotoxic T lymphocyte antigen-4 signaling on tumor immunity, provide a modest clinical beneWt in some patients. The arrival of these drugs in the clinic is a signiWcant advance that we can capitalize on for even better clinical outcomes. The strategic and scientiWcally rational integration of vaccines and other direct immunomodulators with standard cancer therapeutics should lead to therapeutic synergy and high rates of tumor rejection. This review focuses on the use of cyclophosphamide, doxorubicin, and HER-2-speciWc monoclonal antibodies to dissect mechanisms of immune tolerance relevant to breast cancer patients and illustrates how appropriate preclinical models can powerfully inform clinical translation. The immunemodulating activity of targeted, pathway-speciWc, small molecule therapeutics is also discussed. Fully understanding how cancer drugs impact the immune system should lead to the ultimate personalized cancer medicine: eVective combinatorial immunotherapy strategies that simultaneously target signaling pathways essential for tumor growth and progression, and systematically break multiple, distinct immune tolerance pathways to maximize tumor rejection and eVect cure.

Original languageEnglish (US)
Pages (from-to)1299-1305
Number of pages7
JournalCancer Immunology Immunotherapy
Volume61
Issue number8
DOIs
StatePublished - Aug 2012

Fingerprint

Immunotherapy
Breast Neoplasms
Neoplasms
Immune Tolerance
Therapeutics
Vaccines
Monoclonal Antibodies
CTLA-4 Antigen
Pharmaceutical Preparations
Precision Medicine
Immunologic Factors
Doxorubicin
Cyclophosphamide
Immune System
Immunity
Prostatic Neoplasms
Growth

Keywords

  • Breast cancer
  • Chemotherapy
  • Cyclophosphamide
  • Immunotherapy
  • Monoclonal antibody
  • PIVAC 11

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Immunology
  • Immunology and Allergy

Cite this

Re-purposing cancer therapeutics for breast cancer immunotherapy. / Emens, Leisha A.

In: Cancer Immunology Immunotherapy, Vol. 61, No. 8, 08.2012, p. 1299-1305.

Research output: Contribution to journalArticle

Emens, Leisha A. / Re-purposing cancer therapeutics for breast cancer immunotherapy. In: Cancer Immunology Immunotherapy. 2012 ; Vol. 61, No. 8. pp. 1299-1305.
@article{626f59bdff50479cb9a0b5e86b930773,
title = "Re-purposing cancer therapeutics for breast cancer immunotherapy",
abstract = "After decades of work to develop immunebased therapies for cancer, the Wrst drugs designed speciWcally to engage the host anti-Tumor immune response for therapeutic beneWt were recently approved for clinical use. Sipuleucel-T, a vaccine for advanced prostate cancer, and ipilimumab, a monoclonal antibody that mitigates the negative impact of cytotoxic T lymphocyte antigen-4 signaling on tumor immunity, provide a modest clinical beneWt in some patients. The arrival of these drugs in the clinic is a signiWcant advance that we can capitalize on for even better clinical outcomes. The strategic and scientiWcally rational integration of vaccines and other direct immunomodulators with standard cancer therapeutics should lead to therapeutic synergy and high rates of tumor rejection. This review focuses on the use of cyclophosphamide, doxorubicin, and HER-2-speciWc monoclonal antibodies to dissect mechanisms of immune tolerance relevant to breast cancer patients and illustrates how appropriate preclinical models can powerfully inform clinical translation. The immunemodulating activity of targeted, pathway-speciWc, small molecule therapeutics is also discussed. Fully understanding how cancer drugs impact the immune system should lead to the ultimate personalized cancer medicine: eVective combinatorial immunotherapy strategies that simultaneously target signaling pathways essential for tumor growth and progression, and systematically break multiple, distinct immune tolerance pathways to maximize tumor rejection and eVect cure.",
keywords = "Breast cancer, Chemotherapy, Cyclophosphamide, Immunotherapy, Monoclonal antibody, PIVAC 11",
author = "Emens, {Leisha A.}",
year = "2012",
month = "8",
doi = "10.1007/s00262-012-1247-z",
language = "English (US)",
volume = "61",
pages = "1299--1305",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "8",

}

TY - JOUR

T1 - Re-purposing cancer therapeutics for breast cancer immunotherapy

AU - Emens, Leisha A.

PY - 2012/8

Y1 - 2012/8

N2 - After decades of work to develop immunebased therapies for cancer, the Wrst drugs designed speciWcally to engage the host anti-Tumor immune response for therapeutic beneWt were recently approved for clinical use. Sipuleucel-T, a vaccine for advanced prostate cancer, and ipilimumab, a monoclonal antibody that mitigates the negative impact of cytotoxic T lymphocyte antigen-4 signaling on tumor immunity, provide a modest clinical beneWt in some patients. The arrival of these drugs in the clinic is a signiWcant advance that we can capitalize on for even better clinical outcomes. The strategic and scientiWcally rational integration of vaccines and other direct immunomodulators with standard cancer therapeutics should lead to therapeutic synergy and high rates of tumor rejection. This review focuses on the use of cyclophosphamide, doxorubicin, and HER-2-speciWc monoclonal antibodies to dissect mechanisms of immune tolerance relevant to breast cancer patients and illustrates how appropriate preclinical models can powerfully inform clinical translation. The immunemodulating activity of targeted, pathway-speciWc, small molecule therapeutics is also discussed. Fully understanding how cancer drugs impact the immune system should lead to the ultimate personalized cancer medicine: eVective combinatorial immunotherapy strategies that simultaneously target signaling pathways essential for tumor growth and progression, and systematically break multiple, distinct immune tolerance pathways to maximize tumor rejection and eVect cure.

AB - After decades of work to develop immunebased therapies for cancer, the Wrst drugs designed speciWcally to engage the host anti-Tumor immune response for therapeutic beneWt were recently approved for clinical use. Sipuleucel-T, a vaccine for advanced prostate cancer, and ipilimumab, a monoclonal antibody that mitigates the negative impact of cytotoxic T lymphocyte antigen-4 signaling on tumor immunity, provide a modest clinical beneWt in some patients. The arrival of these drugs in the clinic is a signiWcant advance that we can capitalize on for even better clinical outcomes. The strategic and scientiWcally rational integration of vaccines and other direct immunomodulators with standard cancer therapeutics should lead to therapeutic synergy and high rates of tumor rejection. This review focuses on the use of cyclophosphamide, doxorubicin, and HER-2-speciWc monoclonal antibodies to dissect mechanisms of immune tolerance relevant to breast cancer patients and illustrates how appropriate preclinical models can powerfully inform clinical translation. The immunemodulating activity of targeted, pathway-speciWc, small molecule therapeutics is also discussed. Fully understanding how cancer drugs impact the immune system should lead to the ultimate personalized cancer medicine: eVective combinatorial immunotherapy strategies that simultaneously target signaling pathways essential for tumor growth and progression, and systematically break multiple, distinct immune tolerance pathways to maximize tumor rejection and eVect cure.

KW - Breast cancer

KW - Chemotherapy

KW - Cyclophosphamide

KW - Immunotherapy

KW - Monoclonal antibody

KW - PIVAC 11

UR - http://www.scopus.com/inward/record.url?scp=84865803534&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865803534&partnerID=8YFLogxK

U2 - 10.1007/s00262-012-1247-z

DO - 10.1007/s00262-012-1247-z

M3 - Article

C2 - 22454154

AN - SCOPUS:84865803534

VL - 61

SP - 1299

EP - 1305

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 8

ER -